Kate Pickles

Kate Pickles is a health editor for Daily Mail. She specializes in medical stories from research to major treatment breakthroughs. Her reporting covers a range of topics including obesity, cancer, and mental health.

Biography:  https://www.dailymail.co.uk/profile-891/kate-pickles.html

92%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • Dr. Sonya Babu-Narayan has spoken of the potential transformational impact on someone's life due to the kind of improvements seen with semaglutide.
  • HFpEF affects around half a million people in the UK with an annual mortality rate of 10-15% and typical hospitalization once a year.
  • Women lost more weight (9.6%) than men (7.2%)

Deceptions

75%

Examples:

  • Patients were also able to do more exercise and had reduced levels of inflammation.
  • Semaglutide, marketed as Ozempic and Wegovy, helped women lose more weight than men but provided the same benefits to members of each sex who suffer from preserved ejection fraction (HFpEF).
  • The analysis is the first to look at the effects of the jab on men and women separately in relation to preserved ejection fraction (HFpEF), where the heart pumps normally but is too stiff to fill properly.

Recent Articles

Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

Broke On: Sunday, 23 June 2024 Semaglutide, a weight-loss drug marketed as Wegovy or Ozempic, significantly reduces major adverse cardiovascular events (MACEs) by 20% for individuals with overweight or obesity and cardiovascular disease. The SELECT trial revealed that semaglutide users sustained weight loss for up to four years, dropped an average of 10% of their body weight, and showed improvements in heart health regardless of the amount lost. Semaglutide's benefits held up for all subgroups and normal A1c levels at baseline.
Vaping Increases Heart Failure Risk by Nearly 20%: Study

Vaping Increases Heart Failure Risk by Nearly 20%: Study

Broke On: Tuesday, 02 April 2024 A new study found that vaping increases the risk of heart failure by nearly 20%. The research analyzed data from over 175,667 participants in the US and found that those who used e-cigarettes were almost a fifth more likely to develop heart failure compared with people who had never used them. Heart failure is a debilitating condition affecting more than 1 million UK adults and around 6.5million in the US, where it causes symptoms such as shortness of breath, fatigue, and swelling in the ankles or legs.
CRISPR-Cas Gene Editing Technology: Eliminating HIV from Infected Cells and Tissues in the Body

CRISPR-Cas Gene Editing Technology: Eliminating HIV from Infected Cells and Tissues in the Body

Broke On: Tuesday, 19 March 2024 Researchers are using CRISPR-Cas gene editing technology to eliminate HIV from infected cells, providing a new means of targeting HIV DNA. They aim to find ways to target the virus in all types of cells and tissues in the body.